Leonel Cardozo de Menezes e Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Leonel Cardozo de Menezes e Souza has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anderson Faletti
Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-90, RJ, Brazil
1 shared publication - Angus Nichols
Randall Centre for Cell and Molecular Biophysics, King's College London SE1 1UL London, UK
1 shared publication - Besaiz Jose Sánchez-Sánchez
Randall Centre for Cell and Molecular Biophysics, King’s College London, London, United Kingdom
1 shared publication - Brian Marc Stramer
Randall Centre for Cell and Molecular Biophysics, King’s College London, London, United Kingdom
1 shared publication - Carla Pires Veríssimo
Laboratório de Morfogênese Celular (LMC), Instituto de Ciências Biomédicas (ICB), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil
1 shared publication - Helena Lobo Borges
Universidade Federal do Rio de Janeiro
1 shared publication
Latest Publications
- Open Access
- 22 July 2025
- Published by Elsevier in Matrix Biology
- Vol. 140, 113-122
Drosophila Col4a1 Glycine mutations highlight allelic heterogeneity and mechanistic pleiotropy
- 22 July 2025
- Published by Elsevier in Matrix Biology
- Vol. 140, 113-122
Open AccessDrosophila Col4a1 Glycine mutations highlight allelic heterogeneity and mechanistic pleiotropy
- Open Access
p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance
Chemoresistance persists as a significant, unresolved clinical challenge in many cancer types. The tumor microenvironment, in which cancer cells reside and interact with non-cancer cells and tissue structures, has a known role in promoting every aspect of tumor progression, including chemoresistance. However, the molecular determinants of microenvironment-driven chemoresistance are mainly unknown. In this review, we propose that the TP53 tumor suppressor, found mutant in over half of human cancers, is a crucial regulator of cancer cell-microenvironment crosstalk and a prime candidate for the investigation of microenvironment-specific modulators of chemoresistance. Wild-type p53 controls the secretion of factors that inhibit the tumor microenvironment, whereas altered secretion or mutant p53 interfere with p53 function to promote chemoresistance. We highlight resistance mechanisms promoted by mutant p53 and enforced by the microenvironment, such as extracellular matrix remodeling and adaptation to hypoxia. Alterations of wild-type p53 extracellular function may create a cascade of spatial amplification loops in the tumor tissue that can influence cellular behavior far from the initial oncogenic mutation. We discuss the concept of chemoresistance as a multicellular/tissue-level process rather than intrinsically cellular. Targeting p53-dependent crosstalk mechanisms between cancer cells and components of the tumor environment might disrupt the waves of chemoresistance that spread across the tumor tissue, increasing the efficacy of chemotherapeutic agents.
Open Accessp53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance
Chemoresistance persists as a significant, unresolved clinical challenge in many cancer types. The tumor microenvironment, in which cancer cells reside and interact with non-cancer cells and tissue structures, has a known role in promoting every aspect of tumor progression, including chemoresistance. However, the molecular determinants of microenvironment-driven chemoresistance are mainly unknown. In this review, we propose that the TP53 tumor suppressor, found mutant in over half of human cancers, is a crucial regulator of cancer cell-microenvironment crosstalk and a prime candidate for the investigation of microenvironment-specific modulators of chemoresistance. Wild-type p53 controls the secretion of factors that inhibit the tumor microenvironment, whereas altered secretion or mutant p53 interfere with p53 function to promote chemoresistance. We highlight resistance mechanisms promoted by mutant p53 and enforced by the microenvironment, such as extracellular matrix remodeling and adaptation to hypoxia. Alterations of wild-type p53 extracellular function may create a cascade of spatial amplification loops in the tumor tissue that can influence cellular behavior far from the initial oncogenic mutation. We discuss the concept of chemoresistance as a multicellular/tissue-level process rather than intrinsically cellular. Targeting p53-dependent crosstalk mechanisms between cancer cells and components of the tumor environment might disrupt the waves of chemoresistance that spread across the tumor tissue, increasing the efficacy of chemotherapeutic agents.